STANDARD_NAME LU_TUMOR_ENDOTHELIAL_MARKERS_DN SYSTEMATIC_NAME M8822 COLLECTION C2:CGP MSIGDB_URL https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LU_TUMOR_ENDOTHELIAL_MARKERS_DN NAMESPACE Human_NCBI_Gene_ID DESCRIPTION_BRIEF Genes specifically down-regulated in tumor endothelium. DESCRIPTION_FULL Therapeutic strategies based on antiangiogenic approaches are beginning to show great promise in clinical studies. However, full realization of these approaches requires identification of key differences in gene expression between endothelial cells from tumors versus their normal counterparts. Here, we examined gene expression differences in purified endothelial cells from 10 invasive epithelial ovarian cancers and 5 normal ovaries using Affymetrix U133 Plus 2.0 microarrays. More than 400 differentially expressed genes were identified in tumor-associated endothelial cells. We selected and validated 23 genes that were overexpressed by 3.6- to 168-fold using real-time reverse transcription-PCR and/or immunohistochemistry. Among these, the polycomb group protein enhancer of Zeste homologue 2 (EZH2), the Notch ligand Jagged1, and PTK2 were elevated 3- to 4.3-fold in tumor-associated endothelial cells. Silencing these genes individually with small interfering RNA blocked endothelial cell migration and tube formation in vitro. The present study shows that tumor and normal endothelium differ at the molecular level, which may have significant implications for the development of antiangiogenic therapies. PMID 17308118 GEOID AUTHORS Lu C,Bonome T,Li Y,Kamat AA,Han LY,Schmandt R,Coleman RL,Gershenson DM,Jaffe RB,Birrer MJ,Sood AK CONTRIBUTOR Jessica Robertson CONTRIBUTOR_ORG MSigDB Team EXACT_SOURCE Table 3: Fold difference < 0.15 FILTERED_BY_SIMILARITY EXTERNAL_NAMES_FOR_SIMILAR_TERMS EXTERNAL_DETAILS_URL SOURCE_MEMBERS 4969,5350,6401,90161,9687 GENE_SYMBOLS OGN,PLN,SELE,HS6ST2,GREB1 FOUNDER_NAMES